{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:26:26Z","timestamp":1790162786502,"version":"4.1.0"},"reference-count":18,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"4","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JGO"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> Recent guidelines recommend magnetic resonance imaging\u2013based brachytherapy (MRBT) for locally advanced cervical cancer. However, its implementation is challenging within the developing world. This article reports the outcomes of patients with locally advanced cervical cancer treated with chemoradiation and point A\u2013based brachytherapy (BT) using x-ray\u2013 or computed tomography\u2013based planning. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p> Patients treated between January 2014 and December 2015 were included. Patients underwent x-ray\u2013 or computed tomography\u2013based BT planning with an aim to deliver equivalent doses in 2 Gy (EQD2) &gt; 84 Gy<jats:sub>10<\/jats:sub> to point A while minimizing maximum dose received by rectum or bladder to a point or 2 cc volume to &lt; 75 Gy EQD2 and &lt; 90 Gy EQD2, respectively<jats:sub>.<\/jats:sub> The impact of known prognostic factors was evaluated. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> A total of 339 patients were evaluated. Median age was 52 (32 to 81) years; 52% of patients had stage IB2 to IIB and 48% had stage III to IVA disease. There was 85% compliance with chemoradiation, and 87% of patients received four or more cycles. Median point A dose was 84 (64.8 to 89.7) Gy. The median rectal and bladder doses were 73.5 (69.6 to 78.4) Gy<jats:sub>3<\/jats:sub> and 83 (73.2 to 90.0) Gy<jats:sub>3<\/jats:sub>, respectively. At a median follow-up of 28 (4 to 45) months, the 3-year local, disease-free, and overall survival for stage IB to IIB disease was 94.1%, 83.3%, and 82.7%, respectively. The corresponding rates for stage III to IVA were 85.1%, 60.7%, and 69.6%. Grade III to IV proctitis and cystitis were observed in 4.7% and 0% of patients, respectively. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> This audit demonstrates good 3-year outcomes that are comparable to published MRBT series. Conventional BT with selective use of interstitial needles and MRBT should continue as standard procedures until level-I evidence for MRBT becomes available. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jgo.18.00028","type":"journal-article","created":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T19:57:21Z","timestamp":1529611041000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":2,"title":["Standard Chemoradiation and Conventional Brachytherapy for Locally Advanced Cervical Cancer: Is It Still Applicable in the Era of Magnetic Resonance\u2013Based Brachytherapy?"],"prefix":"10.1200","author":[{"given":"Prachi","family":"Mittal","sequence":"first","affiliation":[{"name":"All authors: Tata Memorial Centre, Navi Mumbai, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya","family":"Chopra","sequence":"additional","affiliation":[{"name":"All authors: Tata Memorial Centre, Navi Mumbai, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidharth","family":"Pant","sequence":"additional","affiliation":[{"name":"All authors: Tata Memorial Centre, Navi Mumbai, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh","family":"Mahantshetty","sequence":"additional","affiliation":[{"name":"All authors: Tata Memorial Centre, Navi Mumbai, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Engineer","sequence":"additional","affiliation":[{"name":"All authors: Tata Memorial Centre, Navi Mumbai, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaya","family":"Ghosh","sequence":"additional","affiliation":[{"name":"All authors: Tata Memorial Centre, Navi Mumbai, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeep","family":"Gupta","sequence":"additional","affiliation":[{"name":"All authors: Tata Memorial Centre, Navi Mumbai, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh","family":"Ghadi","sequence":"additional","affiliation":[{"name":"All authors: Tata Memorial Centre, Navi Mumbai, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siji","family":"Menachery","sequence":"additional","affiliation":[{"name":"All authors: Tata Memorial Centre, Navi Mumbai, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamema","family":"Swamidas","sequence":"additional","affiliation":[{"name":"All authors: Tata Memorial Centre, Navi Mumbai, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavanya","family":"Gurram","sequence":"additional","affiliation":[{"name":"All authors: Tata Memorial Centre, Navi Mumbai, India."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam Kishore","family":"Shrivastava","sequence":"additional","affiliation":[{"name":"All authors: Tata Memorial Centre, Navi Mumbai, India."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29210"},{"key":"B2","first-page":"CD008285","author":"Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.07.351"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.brachy.2017.05.003"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2004.12.015"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2005.11.014"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(99)00330-2"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2009.07.001"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2014.11.045"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.06.010"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.11.024"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rrv047"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3747\/co.22.2562"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(12)70552-2"},{"key":"B20","first-page":"E304","author":"Nayak AS","year":"2017","journal-title":"Transabdominal ultrasonography based high dose rate conformal intracavitary brachytherapy in cervical carcinoma."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.09.009"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.brachy.2015.09.002"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.04.043"}],"container-title":["Journal of Global Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JGO.18.00028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T07:06:14Z","timestamp":1653807974000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JGO.18.00028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1200\/JGO.18.00028"],"URL":"https:\/\/doi.org\/10.1200\/jgo.18.00028","relation":{},"ISSN":["2378-9506"],"issn-type":[{"value":"2378-9506","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"2018-06-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}